Lupus Erythematosus

Categories: Rare diseases, Skin diseases, Immune diseases, Genetic diseases, Nephrological diseases, Bone diseases

Aliases & Classifications for Lupus Erythematosus

MalaCards integrated aliases for Lupus Erythematosus:

Name: Lupus Erythematosus 12 50 52 14 69
Lupus 12 50 41 3
Subacute Cutaneous Lupus 50 69
Disseminated Lupus Erythematosus 50
Lupus Erythematosus, Systemic 69
Systemic Lupus Erythematosus 50
Lupus Erythematosus, Discoid 69
Lupus Vulgaris 69
Discoid Lupus 50
Sle 50


External Ids:

Disease Ontology 12 DOID:8857
ICD10 33 L93 L93.0
ICD9CM 35 695.4
NCIt 47 C27153
SNOMED-CT 64 200936003 200944003
UMLS 69 C0409974

Summaries for Lupus Erythematosus

MedlinePlus : 41 what is lupus? lupus is an autoimmune disease. this means that your immune system attacks healthy cells and tissues by mistake. this can damage many parts of the body, including the joints, skin, kidneys, heart, lungs, blood vessels, and brain. there are several kinds of lupus systemic lupus erythematosus (sle) is the most common type. it can be mild or severe, and can affect many parts of the body. discoid lupus causes a red rash that doesn't go away subacute cutaneous lupus causes sores after being out in the sun drug-induced lupus is caused by certain medicines. it usually goes away when you stop taking the medicine. neonatal lupus, which is rare, affects newborns. it is probably caused by certain antibodies from the mother. who gets lupus? anyone can get lupus, but women are most at risk. lupus is two to three times more common in african american women than in caucasian women. it's also more common in hispanic, asian, and native american women. african american and hispanic women are more likely to have severe forms of lupus. what causes lupus? the cause of lupus is not known. what are the symptoms of lupus? lupus can have many symptoms, and they differ from person to person. some of the more common ones are pain or swelling in joints muscle pain fever with no known cause red rashes, most often on the face (also called the "butterfly rash") chest pain when taking a deep breath hair loss pale or purple fingers or toes sensitivity to the sun swelling in legs or around eyes mouth ulcers swollen glands feeling very tired symptoms may come and go. when you are having symptoms, it is called a flare. flares can range from mild to severe. new symptoms may appear at any time. how do i know if i have lupus? there is no single test to diagnose lupus, and it's often mistaken for other diseases. so it may take months or years for a doctor to diagnose it. your doctor may use many tools to make a diagnosis: medical history complete exam blood tests skin biopsy (looking at skin samples under a microscope) kidney biopsy (looking at tissue from your kidney under a microscope) what are the treatments for lupus? there is no cure for lupus, but medicines and lifestyle changes can help control it. people with lupus often need to see different doctors. you will have a primary care doctor and a rheumatologist (a doctor who specializes in the diseases of joints and muscles). which other specialists you see depends on how lupus affects your body. for example, if lupus damages your heart or blood vessels, you would see a cardiologist. your primary care doctor should coordinate care between your different health care providers and treat other problems as they come up. your doctor will develop a treatment plan to fit your needs. you and your doctor should review the plan often to be sure it is working. you should report new symptoms to your doctor right away so that your treatment plan can be changed if needed. the goals of the treatment plan are to prevent flares treat flares when they occur reduce organ damage and other problems treatments may include drugs to reduce swelling and pain prevent or reduce flares help the immune system reduce or prevent damage to joints balance the hormones besides taking medicines for lupus, you may need to take medicines for problems that are related to lupus such as high cholesterol, high blood pressure, or infection. alternative treatments are those that are not part of standard treatment. at this time, no research shows that alternative medicine can treat lupus. some alternative or complementary approaches may help you cope or reduce some of the stress associated with living with a chronic illness. you should talk to your doctor before trying any alternative treatments. how can i cope with lupus? it is important to take an active role in your treatment. it helps to learn more about lupus - being able to spot the warning signs of a flare can help you prevent the flare or make the symptoms less severe. it is also important to find ways to cope with the stress of having lupus. exercising and finding ways to relax may make it easier for you to cope. a good support system can also help. nih: national institute of arthritis and musculoskeletal and skin diseases

MalaCards based summary : Lupus Erythematosus, also known as lupus, is related to systemic lupus erythematosus 1 and c1q deficiency, and has symptoms including cyanosis, exanthema and icterus. An important gene associated with Lupus Erythematosus is TREX1 (Three Prime Repair Exonuclease 1), and among its related pathways/superpathways are Innate Immune System and Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3. The drugs Simvastatin and Hydroxychloroquine have been mentioned in the context of this disorder. Affiliated tissues include t cells, skin and b cells, and related phenotypes are hematopoietic system and immune system

NIH Rare Diseases : 50 lupus is an autoimmune disease that can affect almost every organ in the body. symptoms of lupus can range from very mild to life-threatening. there are three main types of lupus; systemic lupus erythematosus, discoid lupus, and drug-induced lupus. symptoms may include pain or swelling in joints, muscle pain, fever, red rashes, most often on the face (also called the "butterfly rash"), hair loss, chest pain, sensitivity to the sun, swelling in legs or around the eyes, and feeling tired. genetics is thought to play a role in the development of lupus along with other lifestyle and environmental factors. studies suggest that a number of different genes may be involved in determining a person’s likelihood of developing the disease, which tissues and organs are affected, and the severity of disease. lupus is more common in young women. the treatment of lupus depends on the severity of the condition and what parts of the body are affected. treatment may include acetaminophen, ibuprofen, antimalarial drugs, anti-inflammatory steroids, immunosuppressive drugs, and other such as blys-specific inhibitors (belimumab). last updated: 8/9/2017

CDC : 3 Lupus occurs when an unknown trigger causes a person’s own immune system to attack their tissues, damaging the tissues and producing widespread inflammation. There is no known cause or cure for lupus; however, treatments are available.

Wikipedia : 72 Lupus erythematosus is a name given to a collection of autoimmune diseases in which the human immune... more...

Related Diseases for Lupus Erythematosus

Diseases in the Lupus Erythematosus family:

Systemic Lupus Erythematosus Systemic Lupus Erythematosus 14
Systemic Lupus Erythematosus 9 Systemic Lupus Erythematosus 1
Systemic Lupus Erythematosus 11 Systemic Lupus Erythematosus 2
Systemic Lupus Erythematosus 16 Systemic Lupus Erythematosus 3
Systemic Lupus Erythematosus 13 Systemic Lupus Erythematosus 10
Systemic Lupus Erythematosus 12 Systemic Lupus Erythematosus 4
Systemic Lupus Erythematosus 5 Systemic Lupus Erythematosus 7
Systemic Lupus Erythematosus 8 Systemic Lupus Erythematosus 15
Cr2-Related Susceptibility to Systemic Lupus Erythematosus Dnase1-Related Susceptibility to Systemic Lupus Erythematosus
Itgam-Related Susceptibility to Systemic Lupus Erythematosus

Diseases related to Lupus Erythematosus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 837)
id Related Disease Score Top Affiliating Genes
1 systemic lupus erythematosus 1 35.0 TLR5 TREX1
2 c1q deficiency 33.5 C1QA C1QB C1QC
3 lymphoma 31.3 CTLA4 SSB TRIM21
4 myasthenia gravis 31.3 BANK1 FCGR2B PTPN22
5 systemic lupus erythematosus 31.1 BANK1 C1QA C1QB C1QC C4A C4B
6 granuloma annulare 30.4 C1QB C1QC C4A C4B
7 dry eye syndrome 29.5 TRIM21 TROVE2
8 pseudohypoparathyroidism 29.4 CTLA4 PTPN22 STAT4 TRIM21 TROVE2
9 actinic keratosis 26.1 BANK1 C1QA C1QB C1QC C4A C4B
10 lupus erythematosus tumidus 12.5
11 subacute cutaneous lupus erythematosus 12.5
12 discoid lupus erythematosus 12.5
13 lupus erythematosus panniculitis 12.5
14 cutaneous lupus erythematosus 12.5
15 systemic lupus erythematosus 16 12.5
16 neonatal lupus erythematosus 12.4
17 drug-induced lupus erythematosus 12.4
18 systemic lupus erythematosus 2 12.3
19 systemic lupus erythematosus 9 12.2
20 systemic lupus erythematosus 10 12.2
21 pediatric systemic lupus erythematosus 12.2
22 systemic lupus erythematosus 11 12.2
23 chilblain lupus 12.2
24 systemic lupus erythematosus 3 12.1
25 systemic lupus erythematosus 12 12.1
26 systemic lupus erythematosus 4 12.1
27 systemic lupus erythematosus 5 12.1
28 hypertrophic or verrucous lupus erythematosus 12.1
29 systemic lupus erythematosus 14 12.0
30 systemic lupus erythematosus with nephritis 2 12.0
31 systemic lupus erythematosus 13 12.0
32 systemic lupus erythematosus with nephritis 1 12.0
33 systemic lupus erythematosus with nephritis 3 12.0
34 systemic lupus erythematosus 7 12.0
35 systemic lupus erythematosus 8 12.0
36 systemic lupus erythematosus 15 12.0
37 neonatal systemic lupus erythematosus 12.0
38 discoid lupus erythematosus of eyelid 11.9
39 cr2-related susceptibility to systemic lupus erythematosus 11.9
40 dnase1-related susceptibility to systemic lupus erythematosus 11.9
41 itgam-related susceptibility to systemic lupus erythematosus 11.9
42 systemic lupus erythematous, association with 6 11.6
43 vitiligo-associated multiple autoimmune disease susceptibility 1 11.6
44 mixed connective tissue disease 11.5
45 pure red-cell aplasia 11.3
46 sjogren's syndrome 11.3
47 epidermolysis bullosa acquisita 11.3
48 collagen disease 11.3
49 macrophage activation syndrome 11.3
50 retinal vasculitis 11.3

Graphical network of the top 20 diseases related to Lupus Erythematosus:

Diseases related to Lupus Erythematosus

Symptoms & Phenotypes for Lupus Erythematosus

UMLS symptoms related to Lupus Erythematosus:

cyanosis, exanthema, icterus, pruritus, lupus-like rash, seizures

MGI Mouse Phenotypes related to Lupus Erythematosus:

id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.13 PDCD1 PTPN22 SSB STAT4 TLR5 TNFSF4
2 immune system MP:0005387 10.1 BANK1 C1QA C4B CTLA4 FCGR2B PDCD1
3 mortality/aging MP:0010768 9.73 PDCD1 PTPN22 SSB STAT4 TLR5 TREX1
4 liver/biliary system MP:0005370 9.7 C4B CTLA4 FCGR2B PDCD1 PTPN22 TLR5
5 renal/urinary system MP:0005367 9.28 C1QA C4B FCGR2B PDCD1 PTPN22 STAT4

Drugs & Therapeutics for Lupus Erythematosus

Drugs for Lupus Erythematosus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 369)
id Name Status Phase Clinical Trials Cas Number PubChem Id
Simvastatin Approved Phase 4,Phase 1,Early Phase 1 79902-63-9 54454
Hydroxychloroquine Approved Phase 4,Phase 3,Phase 1,Phase 2 118-42-3 3652
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 104987-11-3 445643 439492
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 128794-94-5 5281078
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 24280-93-1 446541
Benzocaine Approved Phase 4,Phase 3,Phase 1 1994-09-7, 94-09-7 2337
Cyclophosphamide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 50-18-0, 6055-19-2 2907
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 53-03-2 5865
belimumab Approved Phase 4,Phase 3,Phase 2,Phase 1 356547-88-1 5957 10451420
Pioglitazone Approved, Investigational Phase 4,Phase 1,Phase 2 111025-46-8 4829
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-78-2 2244
Azathioprine Approved Phase 4,Phase 3,Phase 2,Phase 1 446-86-6 2265
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 1 124-94-7 31307
Metformin Approved Phase 4 657-24-9 14219 4091
Sulfamethoxazole Approved Phase 4 723-46-6 5329
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
Bortezomib Approved, Investigational Phase 4,Phase 2 179324-69-7 387447 93860
Artesunate Approved Phase 4 88495-63-0 6917864 5464098
21 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 1
Calcitriol Approved, Nutraceutical Phase 4,Phase 2 32222-06-3 134070 5280453
Alfacalcidol Approved, Nutraceutical Phase 4 41294-56-8 5282181
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2 58-05-9 143 6006
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 50-14-6 5280793
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 1406-16-2
28 Anticholesteremic Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
29 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
30 Calcium, Dietary Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
31 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
32 Hypolipidemic Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
33 Lipid Regulating Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
34 Rosuvastatin Calcium Phase 4,Phase 2,Phase 1 147098-20-2
35 Vaccines Phase 4,Phase 2,Phase 3,Phase 1
36 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
38 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1
39 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
40 Antimalarials Phase 4,Phase 3,Phase 1,Phase 2
41 Antiparasitic Agents Phase 4,Phase 3,Phase 1,Phase 2
42 Antiprotozoal Agents Phase 4,Phase 3,Phase 1,Phase 2
43 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
44 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
45 Hormones Phase 4,Phase 3,Phase 2,Phase 1
46 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
47 Bone Density Conservation Agents Phase 4,Phase 2,Phase 3,Phase 1
48 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1
49 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1
50 Vitamins Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 639)

id Name Status NCT ID Phase Drugs
1 Study of Endothelial Dysfunction in Systemic Lupus and Its Role in Heart Disease Unknown status NCT00188188 Phase 4 quinipril
2 Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in Systemic Lupus Erythematosus (SLE) Patients With Corticosteroid Therapy and High Low-Density Lipoprotein (LDL) Cholesterol Level Unknown status NCT00866229 Phase 4 Rosuvastatin;Simvastatin
3 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Unknown status NCT00815282 Phase 4 Human papilloma virus vaccine (cervarix)
4 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
5 A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE) Completed NCT01597492 Phase 4
6 The Reduction of Systemic Lupus Erythematosus Flares :Study PLUS Completed NCT00413361 Phase 4 versus hydroxychloroquine
7 Effect of Pioglitazone on Endothelial Function in Premenopausal Women With Uncomplicated Systemic Lupus Erythematosus Completed NCT01322308 Phase 4 pioglitazone;placebo
8 Open-label Trial of Acthar Gel in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus Completed NCT01769937 Phase 4 H.P. Acthar Gel
9 Steroid Induced Osteoporosis in Patients With Systemic Lupus Erythematosus Completed NCT00668330 Phase 4 Ibandronate+alfacalcidol+calcium;placebo ibandronate+alfacalcidol+calcium
10 Tacrolimus for the Treatment of Systemic Lupus Erythematosus With Membranous Nephritis Completed NCT00125307 Phase 4 tacrolimus
11 Aspirin and Statins for Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus Completed NCT00371501 Phase 4 Rosuvastatin;placebo;aspirin;placebo
12 Mycophenolate Mofetil in Systemic Lupus Erythematosus (MISSILE) Completed NCT01101802 Phase 4 Mycophenolate mofetil;sugar pill
13 Effect of Hormone Replacement Therapy on Lupus Activity Completed NCT00392093 Phase 4 Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d
14 Immunogenicity and Safety of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With SLE: a Controlled Study Completed NCT00911521 Phase 4 human papillomavirus vaccination (Gardasil)
15 Efficacy of Fish Oil in Lupus Patients Completed NCT00828178 Phase 4 Omega-3
16 Enteric-coated Mycophenolate Sodium Versus Azathioprine for the Extra-renal Lupus Manifestations Completed NCT01112215 Phase 4 Azathioprine;Enteric-Coated Mycophenolate Sodium
17 Lupus Atherosclerosis Prevention Study Completed NCT00120887 Phase 4 Atorvastatin
18 Long-Acting Tacrolimus for the Treatment of Resistant Lupus Nephritis Completed NCT01206569 Phase 4 Long-acting tacrolimus (Advagraf, Astellas Pharma)
19 Plaquenil for Alopecia Areata, Alopecia Totalis Completed NCT00176982 Phase 4 Hydroxychloroquine
20 Comparing the Efficacy of Tacrolimus and Mycophenolate Mofetil for the Initial Therapy of Active Lupus Nephritis Completed NCT00371319 Phase 4 tacrolimus;mycophenolate mofetil
21 Low-dose Combination of Mycophenolate Mofetil (MMF) and Tacrolimus (Tac) for Refractory Lupus Nephritis Completed NCT01203709 Phase 4 low dose combination of MMF and Tac
22 Comparison of Low Dose Versus High Dose Cyclophosphamide as Induction Therapy in the Treatment of Lupus Nephritis Completed NCT02645565 Phase 4 Cyclophosphamide;Azathioprine;Methylprednisolone
23 A Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Active Systemic Lupus Erythematosus (SLE) Recruiting NCT02953821 Phase 4 Repository corticotropin injection;Placebo gel
24 The Effect of Metformin on Reducing Lupus Flares Recruiting NCT02741960 Phase 4 metformin;placebo
25 Acthar SLE (Systemic Lupus Erythematosus) Recruiting NCT02779153 Phase 4 Acthar low dose (40 U);Acthar high dose (80 U)
26 Prophylactic Trimethoprim/Sulfamethoxazole to Prevent Severe Infections in Patients With Lupus Erythematous Recruiting NCT03042260 Phase 4 Trimethoprim-Sulfamethoxazole;Placebo Oral Tablet
27 Safety and Immunogenicity of a Zoster Vaccine in SLE Recruiting NCT02477150 Phase 4
28 A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE Recruiting NCT03098823 Phase 4 RAYOS;Prednisone
29 Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence of Confounding Polypharmacy Recruiting NCT02270970 Phase 4
30 ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis Recruiting NCT01926054 Phase 4 Acthar gel
31 ACTHar in the Treatment of Lupus Nephritis Recruiting NCT02226341 Phase 4 CellCept;ACTHar gel;ACTHar gel
32 Low-dose VS High-dose IV Cyclophosphamide for Proliferative LN in Children Recruiting NCT01861561 Phase 4 Low-dose intravenous cyclophosphamide;High-dose intravenous cyclophosphamide
33 Efficacy and Safety of Tacrolimus Versus Mycophenolate in Lupus Nephritis Recruiting NCT02630628 Phase 4 Tacrolimus;Mycophenolate mofetil
34 Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE) Active, not recruiting NCT01632241 Phase 4 Standard therapy
35 Acthar for the Treatment of Systemic Lupus Erythematosus in Patients With a History of Persistently Active Disease Active, not recruiting NCT01753401 Phase 4 Acthar;Placebo for Acthar
36 Belimumab Assessment of Safety in SLE Active, not recruiting NCT01705977 Phase 4
37 Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases Not yet recruiting NCT03122431 Phase 4 Thalidomide;Hydroxychloroquine reduced;Hydroxychloroquine high
38 Study Title: Assess the Clinical Efficacy of H.P. Acthar Gel 80 U/ml to Improve the Signs and Symptoms in Subjects With Dry Eye Disease Not yet recruiting NCT03287635 Phase 4 H.P Acthar Gel 80Unit/Ml Repository Injection
39 Efficacy and Safety of Artesunate Plus Standard of Care in Active Lupus Nephritis Not yet recruiting NCT03214731 Phase 4 Artesunate
40 Effect of Simvastatin on Endothelial Function in Premenopausal Women With Systemic Lupus Erythematosus (0733-271)(TERMINATED) Terminated NCT00739050 Phase 4 simvastatin;Comparator: Placebo
41 Trial to Study the Effects of Supplementary Omega-3 on Serum C-Reactive Protein Levels Terminated NCT00578578 Phase 4
42 A Study to Evaluate the Efficacy and Safety of Tacrolimus With Steroid in Korean Lupus Nephritis Patients Terminated NCT01316133 Phase 4 tacrolimus
43 Levothyroxine in Pregnant SLE Patients Withdrawn NCT01276782 Phase 4 Levothyroxine
44 Doxycycline Outcomes in Lupus Erythematosus Withdrawn NCT01014260 Phase 4 Placebo;Doxycycline
45 The Efficacy and Safety of Calcitriol for the Treatment of Lupus Nephritis and Persistent Proteinuria Withdrawn NCT00508898 Phase 4 Calcitriol;Multivitamin
46 The Effect of Milnacipran on Fatigue and Quality of Life in Lupus Patients Withdrawn NCT01359826 Phase 4 Milnacipran
47 Velcade for Proliferative Lupus Nephritis Withdrawn NCT01169857 Phase 4 Velcade
48 Study of GL701 in Men With Systemic Lupus Erythematosus Unknown status NCT00037128 Phase 3 GL701
49 An Open Labeled Pilot Study of Atorvastatin in Systemic Lupus Erythematosus Unknown status NCT00432354 Phase 2, Phase 3 atorvastatin
50 To Assess Prevention of Bone Loss in Women With Lupus Receiving Treatment With Glucocorticoids Unknown status NCT00053560 Phase 3 Prasterone (GL701)

Search NIH Clinical Center for Lupus Erythematosus

Inferred drug relations via UMLS 69 / NDF-RT 48 :

Genetic Tests for Lupus Erythematosus

Anatomical Context for Lupus Erythematosus

MalaCards organs/tissues related to Lupus Erythematosus:

T Cells, Skin, B Cells, Heart, Endothelial, Kidney, Eye

Publications for Lupus Erythematosus

Articles related to Lupus Erythematosus:

(show top 50) (show all 6881)
id Title Authors Year
Association of anti-triosephosphate isomerase antibodies with aseptic meningitis in patients with neuropsychiatric systemic lupus erythematosus. ( 28451873 )
Discoid Lupus Erythematosus Complicated with Pregnancy-induced Hemophagocytic Syndrome. ( 28626188 )
Splenic calcification in systemic lupus erythematosus. ( 28939622 )
Osteoporotic fractures in patients with systemic lupus erythematosus and end stage renal disease. ( 28530467 )
Case of Pediatric Bullous Systemic Lupus Erythematosus Treated with Intravenous Immunoglobulin. ( 27778386 )
Acute acalculous cholecystitis in patients with systemic lupus erythematosus: A unique form of disease flare. ( 28355987 )
Socioeconomic consequences of systemic lupus erythematosus. ( 28520683 )
Plasma ficolin levels and risk of nephritis in Danish patients with systemic lupus erythematosus. ( 27981461 )
Acquired hemophilia as initial presentation in a patient with Systemic Lupus Erythematosus. ( 28523993 )
Cerebral Venous Sinus Thrombosis Presenting Feature of Systemic Lupus Erythematosus. ( 28065614 )
Characterization of patients with systemic lupus erythematosus who meet the diagnostic criteria for TAFRO syndrome. ( 28820362 )
Systemic lupus erythematosus, following prodromal idiopathic thrombocytopenic purpura, presenting with skin lesions resembling malignant atrophic papulosis. ( 28691162 )
What Can We Do When All Collapses? Fatal Outcome of Collapsing Glomerulopathy and Systemic Lupus Erythematosus With Diffuse Alveolar Hemorrhage: Case Report. ( 28457424 )
P-glycoprotein gene MDR1 polymorphisms and susceptibility to systemic lupus erythematosus in Guangxi population: a case-control study. ( 28154898 )
The Systemic Lupus Erythematosus-Associated Single Nucleotide Polymorphism rs1143678 in Integrin I+M Cytoplasmic Tail Generates a 14-3-3IP Binding Site That Is Proinflammatory. ( 27974454 )
SLAMF7 engagement restores defective effector CD8+ T cells activity in response to foreign antigens in systemic lupus erythematosus. ( 28076903 )
MALT lymphoma arising on a background of reactive pulmonary lymphoid hyperplasia in a patient with Systemic Lupus Erythematosus. ( 28945277 )
Role of Angiography in Systemic Lupus Erythematosus-Induced Choroiditis. ( 28362518 )
Systemic lupus erythematosus with ADAMTS13 inhibitor-negative thrombotic microangiopathy treated with combination of mycophenolate mofetil, plasma exchange and steroid. ( 27416846 )
The Histopathological Spectrum of Pseudolymphomatous Infiltrates in Cutaneous Lupus Erythematosus. ( 28654469 )
Successful treatment using corticosteroid combined antibiotic for acute acalculous cholecystitis patients with systemic lupus erythematosus. ( 28682919 )
Bone Disease in Connective TissueA Disease/Systemic Lupus Erythematosus. ( 28900675 )
Anti-neutrophil cytoplasmic antibodies in new-onset systemic lupus erythematosus. ( 28954092 )
Estrogen receptor alpha gene ( ESR1) polymorphism can contribute to clinical findings in systemic lupus erythematosus patients. ( 27681518 )
Efficacy and Safety of Rituximab in the Management of Pediatric Systemic Lupus Erythematosus: A Systematic Review. ( 28602379 )
Imiquimod-induced cutaneous lupus erythematosus with antinuclear antibodies showing a homogenous pattern. ( 28616880 )
Subacute cutaneous lupus erythematosus induced by masitinib. ( 28940367 )
Disseminated discoid lupus erythematosus with a linear lesion on the forearm and hand: A rare presentation and review of literature. ( 28707650 )
An unusual clinical presentation of lupus erythematosus tumidus localized on the thigh. ( 28597962 )
Drugs for discoid lupus erythematosus. ( 28476075 )
Nuclear proteins and apoptotic bodies are found in the lupus band of patients with cutaneous lupus erythematosus. ( 28842330 )
Discoid Lupus Erythematosus Presenting as Upper Eyelid Edema and Erythema. ( 28918619 )
Mycobacterium avium Complex Septic Arthritis Presenting as Osteonecrosis of the Femoral Head in a Patient With Systemic Lupus Erythematosus. ( 28056158 )
Serum Adiponectin Levels in Patients With Systemic Lupus Erythematosus: A Meta-analysis. ( 28937500 )
Atypical Trigeminal Neuralgia: A Rare Neurological Manifestation of Systemic Lupus Erythematosus. ( 28077839 )
Interferon-I+ coincides with suppressed levels of pentraxin-3 (PTX3) in systemic lupus erythematosus and regulates leucocyte PTX3 in vitro. ( 28257596 )
Comparative Analysis of Chilblain Lupus Erythematosus and Idiopathic Perniosis: Histopathologic Features and Immunohistochemistry for CD123 and CD30. ( 28719438 )
Verrucous discoid lupus erythematosus in a child. ( 28194816 )
Pneumococcal infection in patients with systemic lupus erythematosus. ( 28529115 )
The association between systemic lupus erythematosus and bipolar disorderA -A a big data analysis. ( 28525775 )
Association of novel polymorphisms in TMEM39A gene with systemic lupus erythematosus in a Chinese Han population. ( 28427360 )
The deposition of anti-DNA IgG contributes to the development of cutaneous lupus erythematosus. ( 28899632 )
High Expression of B Lymphocyte Stimulator (BLyS) in Lesional Keratinocytes of Patients with Cutaneous Lupus Erythematosus. ( 28833566 )
Cutaneous lupus erythematosus. Quality of life and related factors in a cohort of 260 patients of A CoruA+a, Spain. ( 28832955 )
Tjalma syndrome (pseudo-pseudo Meigs') as initial manifestation of juvenile-onset systemic lupus erythematosus. ( 28522234 )
Association Between TNF-I+ Promoter -308 A/G Polymorphism and Systemic Lupus Erythematosus Susceptibility: A Case-Control Study and Meta-Analysis. ( 27943420 )
Severely Crusted Cheilitis as an Initial Presentation of Systemic Lupus Erythematosus. ( 28794568 )
Central nervous system vasculitis in systemic lupus erythematosus: a case series report in a tertiary referral centre. ( 28420057 )
Pulse dose steroids in severe pulmonary arterial hypertension secondary to systemic lupus erythematosus. ( 28515936 )
Serum interleukin-17 in Egyptian children with systemic lupus erythematosus: is it related to pulmonary affection? ( 27587461 )

Variations for Lupus Erythematosus

ClinVar genetic disease variations for Lupus Erythematosus:

id Gene Variation Type Significance SNP ID Assembly Location
1 TREX1 NM_033629.4(TREX1): c.341G> A (p.Arg114His) single nucleotide variant risk factor rs72556554 GRCh37 Chromosome 3, 48508395: 48508395

Expression for Lupus Erythematosus

Search GEO for disease gene expression data for Lupus Erythematosus.

Pathways for Lupus Erythematosus

Pathways related to Lupus Erythematosus according to GeneCards Suite gene sharing:

(show all 11)
id Super pathways Score Top Affiliating Genes
Show member pathways
13.87 C1QA C1QB C1QC C4A C4B CTLA4
Show member pathways
Show member pathways
11.96 C1QA C1QB C1QC C4A C4B
5 11.91 C1QA C1QB C1QC C4A C4B
Show member pathways
11.85 C1QA C1QB C1QC C4A C4B
Show member pathways
11.68 C1QA C1QB C1QC C4A C4B
8 11.43 C1QA C1QB C1QC C4A C4B
10 11.18 C1QA C1QB C1QC
11 10.92 C1QA C1QB C1QC C4A C4B FCGR2B

GO Terms for Lupus Erythematosus

Cellular components related to Lupus Erythematosus according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 intracellular ribonucleoprotein complex GO:0030529 9.62 SNRPB SSB TRIM21 TROVE2
2 external side of plasma membrane GO:0009897 9.43 CTLA4 FCGR3A PDCD1
3 collagen trimer GO:0005581 9.33 C1QA C1QB C1QC
4 blood microparticle GO:0072562 9.26 C1QB C1QC C4A C4B
5 complement component C1 complex GO:0005602 8.62 C1QA C1QB

Biological processes related to Lupus Erythematosus according to GeneCards Suite gene sharing:

(show all 18)
id Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.91 C1QC CTLA4 FCGR2B FCGR3A TNFSF4
2 immune system process GO:0002376 9.89 C4A C4B CTLA4 PTPN22 TLR5
3 innate immune response GO:0045087 9.7 C1QA C1QB C1QC C4A C4B TLR5
4 inflammatory response GO:0006954 9.67 C4A C4B TLR5 TNFSF4
5 complement activation, classical pathway GO:0006958 9.65 C1QA C1QB C1QC C4A C4B
6 regulation of type I interferon production GO:0032479 9.58 TREX1 TRIM21
7 histone mRNA metabolic process GO:0008334 9.52 SNRPB SSB
8 negative regulation of interleukin-6 secretion GO:1900165 9.46 BANK1 PTPN22
9 positive regulation of apoptotic cell clearance GO:2000427 9.4 C4A C4B
10 regulation of complement activation GO:0030449 9.35 C1QA C1QB C1QC C4A C4B
11 negative regulation of regulatory T cell differentiation GO:0045590 9.32 CTLA4 TNFSF4
12 negative regulation of B cell proliferation GO:0030889 9.27 CTLA4
13 regulation of innate immune response GO:0045088 9.26 PTPN22
14 negative regulation of immune response GO:0050777 9.25 CTLA4
15 negative regulation of cytokine secretion GO:0050710 9.24 TNFSF4
16 negative regulation of B cell activation GO:0050869 9.18 BANK1
17 regulation of adaptive immune response GO:0002819 9.13 TNFSF4
18 complement activation GO:0006956 9.02 C1QA C1QB C1QC C4A C4B

Molecular functions related to Lupus Erythematosus according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 IgG binding GO:0019864 9.16 FCGR2B FCGR3A
2 serine-type endopeptidase activity GO:0004252 9.02 C1QA C1QB C1QC C4A C4B
3 protein tyrosine kinase binding GO:1990782 8.96 PTPN22
4 U2 snRNA binding GO:0030620 8.96 SNRPB TROVE2

Sources for Lupus Erythematosus

9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
52 Novoseek
55 OMIM via Orphanet
59 PubMed
66 SNOMED-CT via Orphanet
68 Tocris
70 UMLS via Orphanet
Loading form....